RSV vaccine study targets frail elderly
NCT ID NCT07203365
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 23 times
Summary
This study looks at how well the RSV vaccine Arexvy works in very old and frail adults (80 years and older) compared to younger seniors (60-65 years). RSV can cause serious lung infections in older people. The goal is to see if the vaccine produces a strong immune response in the oldest group. About 65 participants will receive the vaccine and be monitored for side effects and antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV IMMUNISATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akademiskt specialistcentrum Studieenheten
RECRUITINGStockholm, 113 61, Sweden
Contact Email: •••••@•••••
-
Familjeläkarna SÄBO
RECRUITINGSaltsjöbaden, 13334, Sweden
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.